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Patient I. A 41-year-old woman was admitted to The Meth-
odist Hospital for evaluation of nausea, vomiting, and blurred
vision. The gastrointestinal symptoms began the night before
admission and were not associated with abdominal pain or
diarrhea. She had first experienced blurred vision, most notable
in her left eye, a few hours before she sought medical attention;
her eyes were not painful and had no discharge. Insulin-
dependent diabetes mellitus had been present for 30 years and
was complicated by progressive renal insufficiency. Chronic
maintenance dialysis had been initiated one month before
admission because of end-stage renal failure. Continuous am-
bulatory peritoneal dialysis (CAPD) was the modality chosen,
and she had completed a course of training 4 days before
admission. She was given insulin, 20 U NPH and 10 U regular
in the morning, and 10 U NPH at night; glucose levels were
consistently below 250 mg/dl during the period of CAPD
training. She had had one episode of hyperglycemia in the
previous year but had not experienced ketoacidosis. Other
complications of diabetes included hypertension, controlled
with nifedipine, and diabetic retinopathy, for which she had
received laser surgery. The patient reported self-administration
of illicit intravenous drugs 10 years earlier but denied recent
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use. She gave a history of 30-pack-years of tobacco usage and
social binge drinking but denied chronic alcohol intake. Physi-
cal examination revealed a well-nourished white female in no
distress. Her temperature was 36.9°C; blood pressure, 178/88
mm Hg supine; heart rate, 88 beats/mm; and respiratory rate, 20
breaths/mm.
Funduscopic examination revealed poor visualization of all
quadrants in both eyes but no papilledema. The left pupil did
not react to light. The lungs were clear; the abdomen was soft,
and the area surrounding the dialysis catheter was unremark-
able. Laboratory findings revealed: sodium, 110 mEq/liter;
potassium, 5.1 mEq/liter; chloride, 82 mEq/liter; total C02, 19
mmol/liter; BUN, 75 mgldl; creatinine, 6.1 mg/dl; and glucose,
1704 mg/dl. An arterial blood sample drawn with the patient
breathing room air disclosed a pH of 7.31; PCO2, 39mm Hg;
P0,, 50 mm Hg; and 02 saturation, 84%.
Peritoneal dialysis fluid exchanges were discontinued. She
was given oxygen by nasal cannula, 2 liters/mm, and vomiting
was suppressed with intramuscular administration of metoclo-
pramide. During the first 24 hours after she entered the hospital,
in addition to her customary regimen, she was given an extra
dose of 10 U of regular insulin subcutaneously every 4 hours.
Twelve hours after admission, the blood glucose was 114 mgldl;
subsequent values drawn every 2 hours were 138 mg/dI, 103
mg/dl, and 87 mg/dl. Laboratory data obtained 13 hours after
admission disclosed: sodium, 133 mEq/liter; potassium, 3.4
mEq/liter; chloride, 96 mEq/liter; total CO2. 24 mmol/liter;
BUN, 75 mg/dl; creatinine, 6.4 mg/dl; and blood glucose, 100
mg/dl. Arterial blood gas studies revealed a pH of 7.42; PCO2,
39 mm Hg; P02, 60 mm Hg; and 02 saturation, 91%. The patient
was discharged 24 hours after admission.
Patient 2. A 37-year-old man had been receiving hemodialy-
sis treatments 3 times weekly for 3 years following bilateral
nephrectomy. The medical history was notable for complex
congenital urologic anomalies that required multiple operations,
including suprapubic cystostomy and ureteroileal cutaneous
anastomosis (ileal conduit) at the ages of 8 and 10 years,
respectively. Urolithiasis and several episodes of pyelonephri-
tis subsequently required the surgical removal of stones on
three occasions and long-term treatment with antibiotics. He
ultimately underwent bilateral nephrectomy because of intra-
renal abscesses and recurrent sepsis. The patient also had had
two major episodes of gastrointestinal bleeding due to peptic
ulcer disease about 10 years prior to the initiation of dialysis.
A combination of aluminum hydroxide and calcium carbon-
ate had been prescribed for the control of persistently elevated
serum phosphate levels. For the previous 2 years, he also had
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Fig. 1. Whole body glucose homeostasis in
the early fasting state. (Modified from Ref. 1.)
been given erythropoietin, which had produced a satisfactory
red cell count. Representative, predialysis laboratory data
were: sodium, 137 mEq/liter; potassium, 4.7 mEq/liter; total
C02, 24 mmol/liter; chloride, 98 mEq/liter; serum creatinine,
13.2 mgldl; BUN, 55 mg/dl; calcium, 9.8 mg/dl; phosphorus, 6.9
mg/dl; hemoglobin, 12.7 g/dl; and glucose, 52 mg/dl. Pre-
dialysis plasma glucose levels in the fasting state had been
persistently low, ranging from 44 mg/dl to 63 mg!dl. None of the
medications that he had been given are known to cause hypo-
glycemia.
Discussion
DR. HoRAclo J. ADROGUL (Chief, Renal Section, Veterans
Affairs Medical Center, and Professor of Medicine, Baylor
College of Medicine, Houston, Texas): A common feature, the
lack of renal function, was associated with opposite deviations
in blood glucose in these 2 patients. The first patient's glucose
level rose as high as 1704 mg/dl, whereas the second's fell as
low as 44 mg/dl. This unusual situation, in which the same
disease is associated with both a major increase and a major
decrease in the plasma levels of a metabolic substrate, is
explained by the complex nature of the interaction between
renal function and glucose production and disposal. In this
Forum, I will examine the role of the kidney in glucose
homeostasis and will discuss the physiologic basis and clinical
implications of that role.
Glucose homeostasis
Plasma glucose levels in the normal state can be as low as 60
mgldl during fasting and exercise and as high as 160 mg/dl after
eating. As is well known, glucose levels are determined by the
opposing influences of glucose utilization (removal from the
circulation) and glucose availability (addition to the circula-
tion). Glucose is, of course, derived both from endogenous and
exogenous sources. In the so-called postahsorptive state, that
is, under resting conditions after an overnight fast, 80% of
glucose utilization occurs in insulin-insensitive tissues; the
brain accounts for three-fourths of this amount, and the gut,
renal medulla, and blood cells consume the remainder. Insulin-
sensitive tissues, including muscle, heart, and adipose tissue,
are responsible for only 20% of glucose removal in the postab-
sorptive state. In this state, the liver is the exclusive site of
release of glucose into the circulation. Hepatic glucose derives
primarily from glycogenolysis [11; only 25% of glucose released
from the liver derives from gluconeogenesis (glucose synthe-
sized from three-carbon precursors). The major gluconeogenic
substrates are lactate, pyruvate, glycerol, and alanine. Deple-
tion of hepatic glycogen stores occurs after 20 to 24 hours of
fasting, and the steady removal of glucose from the circulation
by extrahepatic tissues produces mild, well-tolerated hypogly-
cemia (60—80 mg/dl). Sympathetic activity is suppressed by the
fasting state. The decreased blood glucose inhibits insulin
secretion, thereby reducing glucose consumption by insulin-
sensitive tissues and promoting the availability of lipid-derived
gluconeogenic precursors and alternate fuels (that is, glycerol
and free fatty acids, respectively). The increased availability of
fatty acids stimulates ketone production by hepatocytes. The
concomitant increase in glucagon secretion increases further
ketogenesis and gluconeogenesis. These hormonal adjustments
reduce glucose consumption to about one-half the level in the
postabsorptive state, the source of glucose under these condi-
tions being gluconeogenesis, almost exclusively of hepatic
origin. Non-glucose substrates, including ketone bodies and
free fatty acids, provide the remainder of the body's caloric
requirements. Although glucose consumption by the brain is
reduced in prolonged fasting, the brain still accounts for more
than 80% of total-body glucose utilization. If the fasting state
persists for several days, renal gluconeogenesis is activated [1,
2]. Plasma glucose levels during the fasting state generally are
maintained at levels higher (60 mg/dl) than those associated
with cerebral dysfunction. A synopsis of glucose demand and
supply in the early and late fasting states is depicted in Figures
I and 2.
Lactate is the other major metabolic fuel that, in addition to
glucose, is transferred among body tissues in the so-called Con
cycle. This metabolic cycle allows a continuing supply of
energy sources that preserve cell integrity and function [3].
Under normal aerobic conditions, the organs that have an
obligatory glycolytic activity consume glucose and produce
lactate that is exported through the blood stream. These oblig-
atory glycolytic organs include the brain, muscle, skin, and red
cells. In contrast, the liver and renal cortex are responsible for
lactate uptake and production of glucose. Glucose is then
extracted for consumption in tissues with obligatory glycolysis.
The liver has a substantially larger capacity for lactate uptake
than does the kidney, partly because of the relative sizes of the
organs. The liver therefore is generally regarded as dominant in
the process of gluconeogenesis.
Renal tissue is unique in having an extremely low glycogen
content; as a result, net glucose production provides a direct
Supply Demand
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Fig. 2. Whole-body glucose homeostasis in
the prolonged fasting state. (Modified from
Ref. I.)
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Fig. 3. Contribution of the kidney to
endogenous glucose production in conscious
normal and diabetic dogs. Total glucose
production is indicated in parentheses. (From
Refs. 21 and 22.)
index of gluconeogenic activity [4, 5]. The renal cortex, like the
liver, possesses enzymes that both degrade glucose via glycol-
ysis and produce glucose via gluconeogenesis [6]. Lactate and
pyruvate are major substrates for renal and hepatic gluconeo-
genesis; the kidney also utilizes glutamine, glycine, and citrate,
and the liver utilizes alanine. In contrast to the cortex, the renal
medulla and papilla are capable only of glycolysis.
Renal glucose production is substantial in the presence of
adequate substrates and appropriate hormonal influences. In-
deed, in-vitro studies have established that, on a gram-for-gram
basis, gluconeogenesis by the renal cortex exceeds that of the
liver. Yet the kidney's contribution to extrarenal glucose ho-
meostasis appears small under most conditions assessed in
vivo. Only in the presence of sustained hypoglycemia [7, 8],
such as in the hepatectomized animal or in prolonged starvation
with acidosis [2], is the kidney generally thought to release
significant amounts of glucose into the circulation via glucone-
ogenesis. Increased renal gluconeogenesis also has been docu-
mented in animals with decompensated diabetes; the underlying
mechanism is thought to be the associated acidemia and not the
diabetes-induced defect in carbohydrate metabolism [9—11].
Previous failures at demonstrating the renal release of glu-
cose into the circulation [12—14j might be accounted for by
several experimental pitfalls. To date, most in-vivo studies have
been performed in animals under general anesthesia, usually
pentobarbital, a well-characterized inhibitor of calcium trans-
port; renal glucose production is in part a calcium-dependent
process that is stimulated by the addition of the Ca iono-
phore A23187 and inhibited by pentobarbital [15—20]. Further-
more, acute studies in vivo generally involved instrumentation
of the renal circulation, a maneuver known to significantly
reduce the blood flow to the renal cortex, where gluconeogen-
esis occurs, while preserving blood flow to the renal medulla
and papilla, where glycolysis is prominent. Because the arte-
riovenous difference for glucose in the kidney is small and
because of the high renal blood flow rate, it is conceivable that
following the acute surgical instrumentation of the anesthetized
animal, release of glucose by the kidney into the circulation
might not be detected because of an absolutely small (but
biologically significant) arteriovenous difference.
In an effort to overcome these shortcomings, we recently
examined the renal contribution to extrarenal glucose homeo-
stasis in normal conscious dogs and in diabetic dogs [21, 22].
Preparatory surgery performed at least one week prior to the
study included placement of Doppler flow probes on hepatic
and renal vessels, and of exteriorized sampling catheters at
various sites including the femoral artery, and renal, portal, and
hepatic veins. We estimated renal glucose production from the
product of renal plasma flow and the arteriovenous difference
for plasma glucose plus urinary glucose excretion; the values
obtained represent the net renal glucose balance. The net
contribution of the kidney to extrarenal glucose stores (homeo-
stasis) in conscious normal dogs following an overnight fast was
1.6 rmol/kg/min, or 11% of total-body glucose production (Fig.
3). Dogs made diabetic by total pancreatectomy at least one
week prior to study had a major increase in renal glucose
production in the absence of acidemia (blood pH 7.38) or
prolonged fasting. The renal glucose production in conscious
diabetic dogs that did not receive insulin for the previous 24
hours was 9.9 smol/kg/min, or 30% of total-body glucose
production (Fig. 3). The infusion of regular insulin, 1 U/kg, into
the portal vein strongly inhibited renal glucose production in the
Supply Demand
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absence (2.8 mol/kg/min) and presence (1.1 moL/kg/min) of a
simultaneous combined adrenergic blockade with propranolol
and phentolamine. In the absence of insulin, propranolol infu-
sion reduced renal glucose production by 33%; phentolamine
had no measurable effect.
We concluded from these studies that, in the postabsorptive
state, the normal kidney participates in delivering glucose to the
circulation, yet the kidney's role is modest in comparison to
that of the liver. In the diabetic state, however, renal glucose
production is substantial, both in absolute terms and as a
fraction of total-body glucose production. These findings in
conscious normal and diabetic dogs might be applicable to
humans. In decompensated human diabetes, with and without
metabolic acidosis, renal gluconeogenesis is likely substantial.
Renal glucose production, in association with increased hepatic
gluconeogenesis and diminished peripheral glucose uptake,
contributes to the development of hyperglycemia. It should be
recognized, however, that in the presence of normal fluid
volume status and renal excretory function, the concomitant
glucosuria largely compensates for the excessive renal produc-
tion of glucose, thereby preventing extreme hyperglycemia.
The contribution of the kidney in the Con cycle remains
undefined, yet it is believed that most glucose regeneration (that
is, gluconeogenesis) occurs in the liver. We should recognize,
however, that in the presence of significant hyperlactatemia
(lactate higher than 5 mEq/liter) and concomitant acidemia, the
relative participation of the two organs might change substan-
tially. Although in hyperlactatemia, hepatic lactate uptake
increases in production to the lactate load, hepatic glucose
release need not increase significantly, presumably because of a
simultaneous suppression of hepatic glycogenolysis [23]. If the
elevated plasma levels are associated with significant acidemia,
hepatic lactate uptake is significantly impaired, and gluconeo-
genesis is suppressed. In contrast, the combination of hyper-
lactatemia and acidemia, both of which are typically present
during exercise, stimulates renal gluconeogenesis because of
stimulation of the key enzyme in the process, phosphoenol-
pyruvate carboxykinase (PEPCK) [24, 25]. Thus, the renal
contribution to extrarenal glucose homeostasis might be very
important under some physiologic conditions including exer-
cise. Poor exercise tolerance in uremic patients might be due in
part to the impairment in renal gluconeogenesis that alters the
normal transfer of fuels among body tissues. Further studies are
needed to clarify this important topic. In summary, the renal
contribution to extrarenal glucose homeostasis is small under
normal conditions and accounts for approximately 10% of total
available glucose. In prolonged fasting and in diabetes mellitus,
however, the kidney produces 30% or more of the body's
endogenous glucose.
I will now consider the hormonal control of renal glucose
production in greater detail. The control of renal glucose
production has been widely accepted to be closely associated
with renal ammoniagenesis and pH regulation [26—29] and to be
independent of the effects of insulin and glucagon. Studies that
have examined the hormonal influences on renal PEPCK and
gluconeogenesis have concluded that insulin has no significant
effect on glucose metabolism within the renal cortex [24, 25,
30—32]. The enzyme PEPCK catalyzes the decarboxylation of
oxaloacetate to phosphoenolpyruvate and appears as the key
regulatory enzyme in renal gluconeogenesis. Alloxan-induced
diabetes mellitus in the rat produced either no significant
changes or only slightly raised renal PEPCK; the effects on the
kidney contrasted dramatically with the profound increase of
PEPCK in the liver [24]. Short-term starvation increased the
activity of renal PEPCK, but the increase appeared to be
unrelated to the levels of insulin and cortisol. Similar effects
were observed in normal and adrenalectomized animals, and
these changes were considered consequences of the accompa-
nying acidosis [10, 24]. Insulin administration failed to repress
PEPCK synthesis in the renal cortex of diabetic rats [25]. In
addition, transcription of the gene for renal PEPCK was not
affected by diabetes or by glucose refeeding but increased
twofold after 24 hours of starvation and decreased significantly
after bicarbonate feeding [32]. Furthermore, the suppressive
effect of oral glucose administration on the level of renal
PEPCK mRNA is independent of insulin [30]. Although insulin
is considered the major negative modulator of hepatic PEPCK
mRNA transcription and hepatic gluconeogenesis [5], this hor-
mone appears to have no effect on PEPCK in the renal cortex
[30, 32]. Moreover, glucagon, a stimulator of hepatic glucose
formation, exerted no effect on renal gluconeogenesis [33].
At complete variance with these studies are reports from
several investigators of an inhibitory effect of insulin on renal
gluconeogenesis [34—37]. A direct inhibitory action of insulin on
gluconeogenesis has been shown in canine proximal tubule cells
[35—37]. Glucose production in renal cortical slices was higher
in samples obtained from diabetic rats than in samples from
normals; in addition, insulin administration to the diabetic
animals depressed renal glucose production [34]. The suppres-
sive effect of a glucose load on endogenous glucose production
was thought to be restricted to the liver, but this effect is likely
present in the kidney, as a major reduction of renal PEPCK
mRNA occurs after oral glucose administration. The inhibition
of renal PEPCK with an oral glucose load was observed in
normal euglycemic rats, in rats with insulin-induced hypogly-
cemia, and in hyperglycemic rats with streptozotocin-induced
diabetes [30]. Because of these reports and data collected in our
laboratory [21], we conclude that insulin is an important mod-
ulator of renal gluconeogenesis and that insulin-deficient states,
including prolonged fasting and diabetes mellitus, significantly
increase renal glucose production.
Renal physiologists have been interested in gluconeogenesis
mostly because of the relationship between the renal production
of glucose and that of ammonia [38—41]. The oxidative metab-
olism of glucose in the renal cortex is not significantly affected
by acid-base status [6]; by contrast, gluconeogenesis is mark-
edly stimulated whenever intracellular acidosis develops (for
example, in the presence of metabolic acidosis, respiratory
acidosis, or potassium depletion) [9—11, 26]. Differences have
been identified between the regulation of hepatic and renal
gluconeogenesis. Hepatic gluconeogenesis increased in fasted
and diabetic rats independently of their acid-base status [11].
By contrast, renal gluconeogenesis increased during fasting and
diabetes only when acidosis was present [9—11]. Metabolic
acidosis resulting from oral administration of hydrochloric acid
or ammonium chloride leads to increased renal ammoniagenesis
and gluconeogenesis and increased PEPCK activity in the rat.
Ammonium chloride administration, a classic model for evalu-
ating the renal response to metabolic acidosis, inhibits insulin
secretion [42—44]. We therefore speculate that an insulin deficit
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per se might play a major role in the increased renal ammonia-
genesis and gluconeogenesis characteristically observed in ac-
idosis. In addition, insulin resistance develops whenever acido-
sis is present. I will return to this topic.
Glucagon and cortisol act in a synergistic manner on gluco-
neogenesis in the liver and possibly in the kidney [45—48].
Despite claims that glucagon exerts no metabolic effects on
renal tissue, several studies contradict this assertion. Glucagon
stimulates adenylate cyclase activity in various segments of the
rat nephron [19, 49, 50]. In addition, the increased plasma levels
of amino acids that result from the extrarenal actions of
glucagon might stimulate renal glucose production. In normal
and in pancreatectomized dogs evaluated when conscious,
hypoglycemia resulting from insulin administration raised
plasma levels of immunoreactive gut glucagon; this rise in
glucagon levels in turn might stimulate renal gluconeogenesis
and account for the observed increase in renal blood flow,
particularly in the experimental animal with diabetes [51, 52].
Glucocorticoids also increased renal gluconeogenesis in normal
and diabetic rats [53, 54]. Furthermore, angiotensin II [55],
somatostatin [56, 57], growth hormone [58], and atrial natri-
uretic peptides [59] stimulate renal glucose production; the
atrial natriuretic peptides are elevated in the diabetic rat and
have been proposed as potential mediators of hyperfiltration. a
process that might be responsible for the development of
progressive renal insufficiency. In summary, glucagon, cortisol,
and other peptide hormones stimulate renal glucose production
and oppose insulin-mediated inhibitory effects on renal gluco-
neogenesis.
Alpha and beta adrenoreceptors have been identified in the
renal cortex [60—63]. Cyclic AMP is the second messenger for
beta-I and beta-2 agonists; alpha-2 agonists inhibit adenylate
cyclase and cAMP formation. In contrast, alpha-i adrenergic
effects are calcium mediated. The major endogenous catechol-
amines known to alter renal function—epinephrine, norepi-
nephrine, and dopamine [64, 65]—derive from renal efferent
nerves (norepinephrine and dopamine). from the circulation
(epinephrine and norepinephrine), and probably from synthesis
within the kidney (dopamine). The neurotransmitters released
from the noradrenergic nerve terminals appear to act directly on
the renal tubules, including the proximal segment where gluco-
neogenesis occurs. In rat renal cortex, alpha-I and -2 adreno-
receptors appear to coexist on proximal tubular cells. Beta-I
and beta-2 agonists likely modulate glucose production by
inducing changes in cyclic AMP levels [66, 67]. The observation
that cAMP analogues have a significant stimulatory effect on
renal PEPCK transcription (mRNA synthesis) is compatible
with a stimulatory effect of beta adrenoreceptors on renal
glucose production [25]. Stimulation of alpha-i adrenoreceptors
mobilizes phosphatidylinositol, increases production of diacyl-
glycerol and phosphatidic acid, and increases cytosolic cal-
cium; the elevated calcium level in turn might activate protein
kinase C and trigger gluconeogenesis [631. The effects of
activation of alpha-2 adrenoreceptors on gluconeogenesis are
still poorly defined. Perhaps stimulation of renal gluconeogen-
esis due to increased sympathetic activity, and increased
plasma levels of cortisol and glucagon might account, at least in
part, for the hyperglycemia commonly observed in hospitalized
patients. Thus, I believe that the sympathetic nervous system
likely participates in the regulation of renal gluconeogenesis,
especially via a stimulatory role mediated by beta-adrenergic
effects [6, 21].
The kidney plays a significant role in disposing of several
peptide hormones including insulin, glucagon, and growth hor-
mone [68]. The removal of these hormones from the circulation
is followed by their degradation within the renal tissue; urinary
excretion of the intact molecules is negligible. The renal dis-
posal of these low-molecular-weight proteins results from gb-
merular filtration, which precedes tubular uptake and degrada-
tion, largely in the proximal nephron. Renal uptake of peptide
hormones from the peritubular blood and the subsequent cellu-
lar degradation also help eliminate these substances from the
circulation. Renal insulin and glucagon extraction amounts to
15% to 40% and 10% to 20%, respectively, under a variety of
experimental conditions [68]. We recently examined these
parameters in normal conscious dogs and found an extraction of
41% 2% for insulin and 9% 2% for glucagon; these values
were similar in the kidney and liver [22]. The larger mass and
total blood flow of the liver as compared with the kidney
account for a greater total disposal of both insulin and glucagon
by the former organ. Daily renal insulin degradation is approx-
imately 25% of daily pancreatic insulin secretion. The renal
extraction, expressed as percentage of load, remains relatively
constant over the physiologic range of plasma levels for all
peptide hormones. Furthermore, when renal degradation due to
end-stage renal disease is diminished, plasma levels of these
hormones rise. A decrease in the extraction of insulin by
skeletal muscle also has been described in nephrectomized
animals [69, 70]. The alteration in hormonal levels plus a
defective action of these hormones on target tissues are in-
volved in the pathogenesis of the metabolic derangements
observed in renal failure.
Disorders of glucose homeostasis in renal failure
Mild to moderate abnormalities in plasma glucose levels are
commonly encountered in patients with renal failure. Interest-
ingly, deranged renal function can result in the development of
both hyperglycemia and hypoglycemia. Extreme deviations in
plasma glucose are observed less frequently, yet they can lead
to symptomatic hyperglycemia with hyperosmolar encephalop-
athy as well as to life-threatening hypoglycemia.
Hyperglycemia. Hyperglycemia results from an abnormal
balance between insulin availability and counterregulation in
which the effects of the latter are dominant. The development of
renal failure is associated with several metabolic defects in
glucose homeostasis that predispose to moderate hyperglyce-
mia [71—73] and account for the syndrome of "uremic pseudodi-
abetes" (Table 1). Acidemia contributes significantly to the
carbohydrate intolerance of renal failure. Acidemia-induced
hyperglycemia might be due either to diminished plasma insulin
levels or to an effect of acidity on insulin receptor binding and
post-binding effects. Alternatively, the carbohydrate intoler-
ance of acidemia might simply reflect the action of counterreg-
ulatory hormones, including catecholamines and glucagon.
To better understand the mechanisms responsible for the
acidemia-induced insulin insensitivity, let us look at previous
observations on the glycemic response to acute respiratory
acidosis in the dog in the presence and absence of THAM
(Tris-hydroxymethyl-aminomethane). When infused in vivo,
THAM rapidly penetrates cells and acts as a proton acceptor.
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Table 1. Determinants of glucose intolerance or pseudodiabetes" in
renal failure
Acidemia
Insulin resistance in hepatic and peripheral tissues
Abnormal receptor binding
Postreceptor defect
Increased plasma levels of:
Glucagona
Growth hormone
Parathyroid hormone
Increased plasma levels of substrates for hepatic gluconeogenesis
derived from skeletal muscle
Potassium deficiency
a Increased tissue sensitivity also is present.
THAM titrates intracellular carbon dioxide to bicarbonate and
therefore raises intracellular pH. In the early 1960s, Nahas
showed that hyperglycemia is accompanied by an increment in
plasma catecholamines during acute respiratory acidosis, but an
infusion of THAM, which maintained a constant blood pH
during acute hypercapnia, prevented the rise both in plasma
catecholamine levels and glycemia [74]. Although the sympa-
thetic system undoubtedly contributes to glucose intolerance in
acidemia, our demonstration of persistence of hyperglycemia in
the presence of adrenergic blocking agents supports the exist-
ence of other mechanisms responsible for the disturbed gluco-
regulation [75]. Infusion of THAM to normal dogs and humans
induced hypoglycemia; the effect was strikingly dependent on
the pH level, however. When the blood pH was maintained
constant at 7.40 during THAM administration in anesthetized
dogs, hypoglycemia developed, but a reduction of blood pH to
7.00 (acute respiratory acidosis) fully prevented changes in the
plasma glucose level. Moreover, a further reduction of blood
pH to 6.80 during THAM infusion produced hyperglycemia, as
opposed to the hypoglycemia observed in isohydric studies.
The possibility that the THAM-induced hypoglycemia might be
related to an effect of this agent on either insulin secretion,
insulin action, or both evolved from the demonstration that a
THAM infusion in pancreatectomized dogs deprived of food
and insulin for 18 to 24 hours did not reduce plasma glucose
levels [74]. Administration of THAM to dogs pancreatecto-
mized hours before the infusion of this compound, however,
reduced plasma glucose levels to a level similar to that in
normal dogs. These data suggest that increased intracellular pH
in peripheral tissues, possibly skeletal muscle, increases glu-
cose metabolism in the presence of insulin and leads to hypo-
glycemia.
The opposite phenomenon might account for our observa-
tions during acute respiratory acidosis: the decrease in extra-
cellular and intracellular (skeletal muscle) pH was associated
with hyperglycemia in the presence of normal or increased
plasma insulin levels; hyperglycemia appeared to be mediated
by reduction of insulin binding to its receptor and decreased
tissue sensitivity to the hormone [75]. We concluded that the
carbohydrate intolerance found in acidemia is neither the result
of decreased plasma insulin levels nor is it prevented by
sympathetic blockade. Rather, our insulin infusion studies with
euglycemic clamp showed that the abnormal glucoregulation in
acidemia results from effects on hepatic and extrahepatic tis-
sues [75]. As Figure 4 illustrates, a sizable reduction in the rate
0
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Fig. 4. Rate of glucose infusion required to maintain euglycemia
during insulin infusion studies in normal and acidemic dogs (pHa =
7.18). Open area in each column represents the value in acidemic dogs;
the entire column is the value in normal dogs. (Modified from Ref. 75.)
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Fig. 5. Plasma glucose and insulin levels from arterial samples of
normal and acidemic dogs during insulin infusion studies with eugly-
cemic clamp (pHa = 7.18). (Modified from Ref. 75.)
of glucose infusion was required to maintain euglycemia in dogs
with severe acidemia (pH = 7.18) during euglycemic clamp.
Figure 5 depicts the corresponding arterial plasma levels of
glucose and insulin. An identical insulin infusion rate in normal
and acidemic animals resulted in higher plasma insulin levels in
the latter group; this finding suggested reduced tissue extraction
of insulin. We further examined this issue in normal and
acidemic dogs exposed to an intravenous glucose load without
the exogenous administration of insulin. The ratio of arterial-
to-portal vein insulin levels increased significantly at lower
blood pH values (Fig. 6); this finding suggested a pH-induced
change in hepatic insulin extraction. A direct evaluation of the
effect of systemic pH on the hepatic extraction of insulin in the
presence and absence of adrenergic blocking agents has con-
clusively established that acidemia decreases insulin uptake by
the liver (Fig. 7). Adrenergic blockade did not significantly alter
7
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the effects of acidemia on the ratio of arterial-to-portal vein
insulin levels (Fig. 6) or on the hepatic extraction of insulin (Fig.
7). Thus, acidemia per se, independent of the sympathetic
nervous system, accounts for the diminished uptake of insulin
by the hepatocytes. This effect on the liver led us to propose
that an abnormal interaction between insulin and target tissues,
hepatic and extra' patic, might be involved in the acidemia-
induced insulin res. ,tance [75]. Consistent with this concept is
our recent demonstration of the opposite phenomenon, that is,
increased tissue sensitivity to insulin, that occurred in associa-
tion with increased hepatic insulin extraction in dogs treated
chronically with glyburide, an oral hypoglycemic agent widely
used in the treatment of type-LI diabetes mellitus [76]. We also
noted that both metabolic acidosis resulting from the infusion of
mineral acids and respjratory acidosis raised plasma levels of
both glucagon and glucose [771. This finding suggests that a
primary stimulation of glucagon secretion is the expected
response to an increased hydrogen ion concentration in body
fluids. Significant pH effects in the insulin-to-glucagon molar
ratio in portal vein samples were not found in our studies; the
potential effect of changes in glucagon levels during acidosis
therefore seems to be properly neutralized by parallel alter-
ations in insulin levels. Thus glucagon's action on its major
target organ—the liver—does not appear to have a significant
role in the increment in plasma glucose levels observed in
acidosis.
The reduced renal extraction of peptide hormones character-
istic of renal failure accounts in part for the rise in plasma levels
of glucagon, growth hormone, and parathyroid hormone, and
these three substances have been implicated in the glucose
intolerance of uremia [71—73]. Insulin resistance in renal failure
has been documented with direct measurements of glucose
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turnover and involves the skeletal muscle and adipose tissue
[72]. Because fasting uremic patients remain normoglycemic
despite high plasma insulin levels, an abnormal carbohydrate
tolerance must be present. Glucose uptake by the forearm in
patients with renal failure who receive an insulin infusion is
substantially lower than in normal controls [71]. Furthermore,
tissue sensitivity to insulin in uremia increases after dialysis;
uremia thus is responsible for the deranged glucose homeostasis
[78]. In contrast to the tissue hyporesponsiveness to insulin in
uremia, sensitivity to glucagon is heightened [79]. The altered
response to the major glucoregulatory hormones in uremia
might account for the increased hepatic glucose production and
decreased uptake by adipose and muscle tissues. Patients with
chronic renal failure had increased hepatic gluconeogenesis
from alanine and a relative impairment of peripheral glucose
disposal. The increased alanine production from skeletal mus-
cle in chronic uremia results from an accelerated breakdown of
muscle proteins, from an inhibition of protein synthesis, or from
Fig. 7. Hepatic extraction of insulin in dogs
with intact adrenergic systems (top) and
infusion of adrenergic blocking agents
(bottom, includes phentolamine infusion,
— propranolol infusion, and simultaneous
7.40 infusion of both blockers) as a function of
blood pH. (Reproduced with permission of the
American Physiological Society, Ref. 75.)
both mechanisms [80]. The magnitude of the increased hepatic
glucose production in renal failure appears to be too small to
explain the degree of glucose intolerance observed. Thus in
peripheral tissues, the impairment of glucose disposal due to
insulin resistance, which probably occurs at the receptor and
postreceptor levels, is considered significant. Total-body potas-
sium stores are diminished in uremia, and a potassium-deficient
state is present in some of these patients. Glucose intolerance is
an important metabolic derangement observed in potassium
depletion and results in a deficient insulin release in response to
hyperglycemia and a reduced content of glycogen in skeletal
muscle [81, 821.
The diminished or absent urinary excretion of glucose at
plasma glucose levels higher than the "renal threshold" in
patients with renal failure plays a critical role in generating and
maintaining severe hyperglycemia [83]. In contrast to this
mechanism of glucose retention due to lack of renal function
and excretion, "uremic pseudodiabetes" predisposes to only
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moderate hyperglycemia. A simple calculation demonstrates
the virtual impossibility of maintaining plasma glucose levels
substantially higher than 400 mgldl in the presence of normal
renal function because of the magnitude of obligatory gluco-
suria. The difference between the patient's plasma glucose and
the renal "threshold" of approximately 180 mgldl, multiplied by
the daily rate of renal ultrafiltration, allows us to estimate the
expected level of glucosuria. Assuming a normal GFR, the
amount of glucose that escapes reabsorption at a plasma level of
400 mg/dl is approximately 400 g/day. Whole-body glucose
utilization is approximately 200 glday under euglycemic condi-
tions but, in the presence or absence of insulin, this rate
increases in proportion to the glucose concentration during an
acute elevation. This effect is substantially intensified, of
course, in the presence of high insulin levels. Doubling the
plasma glucose concentration in the presence of physiologic
levels of insulin doubles glucose consumption. Hyperglycemia
increases both oxidative and non-oxidative glucose disposal.
Glucose transport increases acutely in tissues having high
transport capacity relative to metabolic capacity (brain and red
cells) and in those having low transport capacity relative to their
metabolic capacity (muscle, heart, adipose tissue). It follows
that in patients with severe hyperglycemia and adequate renal
function, substantial glucose removal, 600 to 1000 g/day, results
from glucosuria plus internal disposal. An equal amount of
glucose must enter the circulation to satisfy these demands in
steady-state, severe hyperglycemia. However, endogenous glu-
cose production by the liver is suppressed by hyperglycemia,
even in the absence of inhibitory effects of the associated
changes in insulin and glucagon levels. The inhibitory effect of
hyperglycemia on the liver is due to inhibition of both glyco-
genolysis and gluconeogenesis. Thus, unless an extremely large
exogenous source of glucose is present (such as diet or paren-
teral nutrition), severe hyperglycemia will not be sustained in
the absence of renal failure. A possible exception to the
obligatory presence of renal failure is the patient with decom-
pensated diabetes, who has an exceptionally high level of
endogenous glucose production, that is, in excess of three times
the normal value observed in the fasting state.
Renal dysfunction must be present to initiate and sustain
extreme hyperglycemia in patients with a full-blown syndrome
of hyperglycemic hyperosmolar encephalopathy. The predis-
posing conditions include the presence of uncontrolled diabetes
mellitus and renal failure. This syndrome, usually associated
with glucose levels above 600 mg/dl, has high morbidity and
mortality rates. Typically, patients are over 50 years of age and
have mild type-I! diabetes, but as many as 50% have no history
of diabetes. The precipitating factors of severe hyperglycemia
and hyperosmolar encephalopathy are fluid deficit (Table 2) and
glucose load of exogenous and endogenous origin (Table 3). The
syndrome often is observed in patients with poor fluid intake
(patients who are weak and unable to perceive or respond to
thirst because of sedation, stroke, or other causes) and abnor-
mal fluid losses due to osmotic diuresis, vomiting, diarrhea,
fever, or diuretics. Patients receiving tube-feeding solutions,
parenteral hyperalimentation, and peritoneal dialysis with a
high glucose concentration in the dialysate, such as the first
patient presented, also are prone to developing this hyperos-
molar, hyperglycemic, nonketotic syndrome. The major deter-
minant of marked hyperglycemia in the presence of abnormal
Table 2. Fluid deficit as precipitating factor of severe hyperglycemia
and hyperosmolar encephalopathy
Physiologic derangement Clinical entity
Poor water intake
Relatively preserved CNS Elderly/nursing home patients
function
Major CNS abnormality Cerebrovascular accident
Subdural hemorrhage
Increased urinary fluid loss Large osmotic diuresis
Diuretics
Extrarenal fluid loss
Gastrointestinal Gastroenteritis, peptic ulcer
disease, gastrointestinal
bleeding, pancreatitis
Skin Heat stroke, burns
Table 3. Exogenous and endogenous glucose load as precipitating
factors for severe hyperglycemia and hyperosmolar encephalopathy
Physiologic
derangement Clinical entity
Increased glucose Highly sweetened drinks
intake Enteral or parenteral force-
feeding
Hyperalimentation
Peritoneal dialysis
Increased endogenous
glucose production
Stress Psychologic/physical
trauma
Infection Pneumonia, pyelonephritis,
sepsis
Major illness Myocardial infarction
Medication Corticosteroids, phenytoin,
calcium-channel blockers
glucoregulation is the impaired renal function, due in most
cases to volume depletion, which limits or prevents glucosuria.
Thus, whenever a major derangement in glucoregulation devel-
ops, the overall level of renal function plays a critical role in
determining disturbances in the electrolyte [84—86] and non-
electrolyte composition of the plasma, including the blood
glucose levels.
Patients without a history of diabetes mellitus who develop
advanced renal failure can exhibit glucose intolerance, mani-
fested as hyperglycemia both after meals and in the fasting
state. Dietary management often successfully controls this
metabolic abnormality, but hyperglycemia sometimes requires
a more aggressive therapeutic approach. In the latter circum-
stance, neither a calorie-deficient diet nor oral hypoglycemic
agents should be used (with the possible exception of glipizide,
the most rapid and short-acting sulfonylurea available). The
patient must be given carefully titrated insulin therapy; the
amount of insulin needed to correct the hyperglycemia cannot
be predicted. In spite of the tissue hyporesponsiveness to
insulin that accompanies uremia, insulin requirements are char-
acteristically reduced in diabetic patients who develop renal
failure [87]. I will discuss the determinants of this paradoxical
situation in the next section.
Hypoglycemia. Renal insufficiency is probably the second
most common cause of hypoglycemia after insulin therapy [88,
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Clinical entity
Dietary neglect, acute and
chronic
Prolonged fasting
Chronic malnutrition
Heart failure
Neoplasms
Adrenal, thyroid deficiency
Alcohol intake
Oral hypoglycemic agents
Beta-blockers, other medications
(see Table 6)
Hepatic disease
Renal failure
Insulin therapy
Sepsis
89]. In a general population of hospitalized patients who devel-
oped hypoglycemia, nearly 50% had chronic renal insufficiency
[881 and such patients do poorly. Among severe episodes of
drug-induced hypoglycemia, more than 75% occurred in pa-
tients with renal or hepatic dysfunction or both [891. Spontane-
ous hypoglycemia usually develops only in patients with renal
failure of prolonged duration; approximately one-half of these
patients have had diabetic nephropathy [89]. Contributing fac-
tors that play a role in the duration and severity of hypoglyce-
mia in renal failure include the simultaneous presence of
undernutrition, hepatic dysfunction, other illness, and drug
effects [90, 91]. Diabetes mellitus is the cause of end-stage renal
failure in about one-third of ESRD patients, and a significant
fraction of these patients require insulin administration; the risk
of developing hypoglycemia under these circumstances is ex-
ceptionally high.
Let us review the causes and mechanisms of hypoglycemia in
renal failure and the distinct signs and symptoms of hypogly-
cemia in this condition [90—94]. The pathophysiology of hypo-
glycemia and the clinical conditions in which it develops in
patients with renal failure are summarized in Tables 4 and 5.
The most important predisposing mechanism to hypoglycemia
is diminished glucose availability due to substrate limitation.
Deprivation of calories because of poor appetite, upper gastro-
intestinal symptoms, or simple neglect—particularly in old
patients—are leading causes of hypoglycemia. The defective
elimination of drugs that predispose to hypoglycemia represents
a major mechanism leading to depressed plasma glucose in
renal failure. Sympathetic counterregulatory response is de-
pressed in uremia and contributes to hypoglycemia due to
inadequate hepatic glycogenolysis and gluconeogenesis. Defi-
cient gluconeogenesis is magnified by the loss of alanine during
hemodialysis [89]. The decreased renal insulin extraction can
result in hyperinsulinemia, which counteracts tissue insulin
Table 6. Drug-induced hypoglycemia
Alcohol
Insulin, sulfonylureas
Nonselective beta-adrenergic blockers
(propranolol, pindolol)
Acetaminophen, salicylates,
Propoxyphene, phenylbutazone,
quinine
Antibacterial Trimethoprim-sulfamethoxazole,
sulfonamides, pentamidine
Antiarrhythmic Quinidine, disopyramide
Anticoagulants Warfarin
_____________________ —
resistance and fosters hypoglycemia. However, insulin levels
most often are normal in non-diabetic uremic patients. The
half-life of endogenous insulin as well as that of exogenous
insulin is prolonged in patients with advanced renal failure. The
net effect is the possible occurrence of an exaggerated hypo-
glycemic response, which has been proposed to account in part
for the decreased insulin requirements in diabetics with renal
failure [87]. The insulin dosage in insulin-treated diabetics
decreases as the severity of renal insufficiency increases, and
insulin may not be required when end-stage renal failure is
reached [89]. Normalization of glucose tolerance tests as a
result of the development of renal failure also has been reported
in diabetic patients [891. The presence of fasting hyperinsuline-
mia in non-diabetic patients with advanced renal failure might
be due partly to the presence of significant hyperkalemia.
Elevated serum potassium levels such as those commonly
found in uremic patients increase the plasma insulin concentra-
tion in humans and experimental animals. Clearly, an associa-
tion exists among hyperkalemia, hypoglycemia, and hyperinsu-
linemia. It has been difficult to establish with certainty,
however, whether the hypoglycemia and relatively high insulin
levels observed in non-diabetic patients with renal failure and
hyperkalemia are due to the electrolyte abnormality, as many
other factors contributing to hypoglycemia are operating simul-
taneously. Insulin levels also contribute to the modulation of
serum potassium [77]. The diminished renal gluconeogenesis
characteristic of renal failure adds to the propensity for hypo-
glycemia. Heart failure, neoplasms and endocrine deficien-
cies—especially of the adrenal and thyroid glands—also play a
role in the development of hypoglycemia in uremic patients.
The pathogenesis of hypoglycemia in these diseases varies and
includes poor dietary intake, gastrointestinal malabsorption,
depletion of glycogen stores, and diminished hepatic gluconeo-
genesis partly due to insufficient production or delivery of
substrates.
The second most important mechanism of hypoglycemia in
all patients with renal failure is drug-induced hypoglycemia due
to alcohol, insulin, oral hypoglycemic agents, or several drugs
that are not effectively eliminated because of renal failure [951.
Table 6 lists the drugs that have been implicated repeatedly in
the development of hypoglycemia in patients with normal and
abnormal renal function. Other than insulin, the most common
exogenous agents causing hypoglycemia in adults presenting to
the emergency room are alcohol and sulfonylureas; these two
substances account for more than 50% of all cases of irrevers-
ible brain damage secondary to hypoglycemia. Renal failure
with and without hepatic disease is commonly observed in
Table 4. Mechanisms of hypoglycemia in renal failure
Diminished glucose availability due to substrate limitation
Defective elimination of drugs that predispose to hypoglycemia
Impaired sympathetic counterregulatory response
Inappropriate elevation of insulin levels and effects
Lack of renal contribution, to extrarenal glucose homeostasis
Table 5. Causes of hypoglycemia in renal failure
Physiologic derangement
Recreational
Hypoglycemic
Antihypertensive
Analgesic
Anti-inflammatory
Caloric deprivation
Diminished hepatic release of
glucose
Reduced renal release of
glucose
Excess peripheral utilization
of glucose
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patients with severe hypoglycemia due to sulfonylurea therapy
and excessive alcohol intake [89, 95]. Several mechanisms are
involved in alcoholic hypoglycemia [96]. Inadequate glycoge-
nolysis is due to depletion of glycogen stores as a result of
malnutrition, prolonged fasting, and liver disease. Alcohol
metabolism depletes hepatic nicotinamide adenine dinucle-
otide, which is essential for gluconeogenesis from lactate and
from other precursors. Ethanol inhibits the hepatic uptake of
the gluconeogenic precursors: lactate, alanine, and glycerol. In
addition, alcohol inhibits alanine release from skeletal muscle
and suppresses counterregulation by inhibiting the release of
growth hormone and adrenocorticotrophic hormone. Alcoholic
hypoglycemia can develop many hours after alcohol ingestion,
even when the patient no longer has detectable blood alcohol
levels. Hypoglycemia most commonly occurs in chronically
malnourished and fasting alcoholic patients. After a prolonged
fast, the normal kidney contributes as much as 45% of endog-
enous glucose via gluconeogenesis [2], so renal failure substan-
tially increases the risk of alcohol-induced, profound hypogly-
cemia.
All sulfonylureas currently in use for the treatment of type-Il
diabetes mellitus have caused severe refractory hypoglycemic
coma, primarily in patients with renal failure [95]. Chlorpropa-
mide, the oral agent most frequently implicated in hypoglyce-
mic episodes, is almost exclusively eliminated by the kidney;
thus this drug is contraindicated in patients with renal failure.
Tolbutamide and acetohexamide also have prolonged half-lives
in patients with advanced renal failure and can cause recurrent
hypoglycemia in these patients. In contrast to these agents, the
second-generation sulfonylureas, including glyburide and glip-
izide, are metabolized in the liver; the half-lives of these agents
remain unaltered in moderate renal insufficiency [89]. However,
active metabolic derivatives from glyburide do accumulate in
renal failure; thus glyburide should not be used if creatinine
clearance is less than 30 mI/mm. The short-acting, second-
generation drug glipizide also should be avoided in advanced
renal failure [891.
Non-selective beta-adrenergic blocking agents such as pro-
pranolol and pindolol cause hypoglycemia because they dimin-
ish counterregulation to hypoglycemia, including the glucagon-
mediated hepatic glycogenolysis and gluconeogenesis. This
hypoglycemic effect, more severe in patients with renal failure,
has been described both in diabetic and nondiabetic patients.
Propranolol is the drug most often associated with hypoglyce-
mia in hemodialysis patients, particularly when a glucose-free
dialysate is used [89—92]. The addition of glucose to the dialy-
sate diminishes the risk of hypoglycemia in patients receiving
non-selective beta blockers for control of hypertension, angina,
or arrhythmias.
The risk of hypoglycemia is substantial in diabetics with renal
insufficiency who are given both a sulfonylurea and salicylates.
Salicylates and other drugs including phenylbutazone, acetamin-
ophen, propoxyphene, sulfonamides, and warfarin can potenti-
ate the hypoglycemic effect of oral hypoglycemic agents by
inhibiting hepatic metabolism of the drug. Trimethoprim-sul-
famethoxazole, which also potentiates the effects of oral sulfo-
nylureas, causes hypoglycemia in patients with renal insuffi-
ciency, yet this drug has not been held responsible for
hypoglycemia in diabetic patients with normal renal function.
The risk of hypoglycemia is also present in non-diabetic pa-
tients with renal failure receiving any of these compounds.
Sulfonamides, like the structurally similar sulfonylureas, de-
crease plasma glucose levels, especially in patients with renal
failure. Moderate amounts of salicylates also can produce
hypoglycemia due to renal-failure-induced drug accumulation.
Most likely, salicylates and acetaminophen induce hypoglyce-
mia by inhibiting hepatic gluconeogenesis, partly through their
ability to uncouple oxidative phosphorylation [95].By contrast,
drug-induced stimulation of insulin secretion has been proposed
to account for the development of hypoglycemia with quinine,
guanidine, and pentamidine [95]. Disopyramide, a quinidine-
like antiarrhythmic drug, also produces hypoglycemia in pa-
tients with renal or hepatic dysfunction by a mechanism pre-
sumably similar to that of quinine [95]. Excessive peripheral
utilization and depressed endogenous glucose production are
involved in the hypoglycemia observed in sepsis and after
insulin overdose.
The existence of an impaired sympathetic counterregulatory
response to hypoglycemia in renal failure is important not only
from a pathophysiologic point of view, but also in terms of the
clinical presentation of hypoglycemia. The typical symptoms of
hypoglycemia in adult patients are conveniently classified as
those due to sympathetic discharge and those secondary to
inadequate glucose delivery to the brain (neuroglycopenia) [97].
The sympathetic symptoms, which generally develop at higher
plasma glucose levels than do the neuroglycopenic manifesta-
tions, usually are evident when the plasma glucose reaches 50
mg/dl to 70 mg/dl. These symptoms include hunger, irritability,
palpitations, tremors, and sweating, and usually are observed in
well-nourished individuals who develop acute hypoglycemia.
However, patients suffering from hypoglycemia due to severe
caloric restriction or renal failure fail to manifest sympathetic-
mediated symptoms, and their only manifestations are those of
neuroglycopenia (Table 7). Two reasons account for the lack of
sympathetic symptoms in the hypoglycemia of renal failure.
First, the fasting state inhibits the sympathetic system, whereas
feeding results in its stimulation. Thus, overall undernutrition
and caloric/substrate limitation in patients with uremia and
hypoglycemia suppress the sympathetic response. Second,
end-stage renal failure is commonly accompanied by a signifi-
cant autonomic neuropathy resulting in a lack of sympathetic
counterregulation. This defect is magnified in patients with
renal failure due to diabetes mellitus in whom the autonomic
neuropathy is often severe and the risks of hypoglycemia are
highest.
Table 7. Signs and symptoms of hypoglycemia in patients with renal
failure
Neuroglycopenic manifestations
—50 mg/dl
—30 mg/dl
—10 mg/dl
Sympathetic manifestations:
Headache, blurred vision,
dizziness, lack of
coordination
Lethargy, variable degrees
of coma
Convulsions, permanent
brain damage, death
Usually absent
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Concluding remarks
The complex role of the kidney in glucose homeostasis
accounts for both hyperglycemia and hypoglycemia in ad-
vanced renal failure. Among the most important factors that
determine whether plasma glucose reaches abnormally high or
low values are overall nutritional status, magnitude of current
caloric intake, and drug administration. Vacillating blood glu-
cose levels in patients with diabetes mellitus and renal disease
make achieving tight metabolic control especially difficult.
Because renal failure alters caloric intake and insulin metabo-
lism, insulin requirements can vary markedly. Proper diabetic
management demands that clinicians anticipate the possibility
of insulin resistance and the need to change insulin dosage; in
this context, we should note that glucose intolerance improves
with dialysis.
The first patient presented here illustrates extreme hypergly-
cemia in a woman with type-I diabetes mellitus and end-stage
renal failure being treated with continuous ambulatory perito-
neal dialysis. The additive effects of anuria, high glucose
concentration in peritoneal dialysis fluid (all exchanges were
2.5% dextrose prior to admission), and poor metabolic control
of type-I diabetes mellitus accounted for the development of the
hyperosmolar hyperglycemic syndrome observed in this pa-
tient.
A potentially more serious complication is hypoglycemia in
patients with end-stage renal failure. Hypoglycemia is relatively
common and has a poor prognosis in patients with renal failure.
Patient 2 had persistent hypoglycemia in the absence of a
history of a medication that might have been responsible for this
abnormality. This patient had had bilateral nephrectomy, so the
loss of renal glucose production and renal insulin disposal
predisposed him to hypoglycemia; in addition, he had received
hemodialysis, as opposed to the first patient, who had received
peritoneal dialysis therapy with its attendant, sizable glucose
load. Alcohol intake, concomitant liver disease, and sepsis are
prominent cofactors in the pathogenesis of hypoglycemia in
patients with renal failure. Proper nutrition, the judicious use of
any medication that has the potential for inducing hypoglyce-
mia, early detection and treatment of associated diseases, and
the use of dialysate fluid with glucose in hemodialysis patients
can diminish the risks of this potentially lethal complication.
Questions and answers
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Insulin
resistance and the resultant hyperinsulinemia are now consid-
ered risk factors for atherosclerotic vascular disease. To the
extent that dialysis ameliorates these metabolic abnormalities
of chronic renal failure, hyperinsulinemia might figure as an
additional parameter to be considered regarding initiation of
dialysis. In your view, how much of the hyperinsulinemia is due
to the acidemia of chronic renal failure and how much to the
uremia itself? Does this issue strengthen the case for maintain-
ing blood pH close to normal in patients with chronic renal
insufficiency? Have there been any studies in uremic animals in
which attempts were made to learn how much of the hyperin-
sulinemia and associated defects of uremia are due to the
prevailing acidemia?
DR. ADROGUE: Although the association between insulin
resistance and an increased risk of atherosclerotic cardiovascu-
lar disease is well documented, the roles of insulin resistance
and the resultant hyperinsulinemia in the pathogenesis of this
illness have not been conclusively established [98—100]. With
respect to the hyperinsulinemia observed in patients with
chronic renal failure, this abnormality is not always present
and, when it occurs, it is often mild. Most patients with uremia
have insulin resistance, which should lead to increased insulin
secretion unless this process is impaired by renal failure.
Consequently, plasma insulin levels can be normal or even low
in uremic patients with a decreased insulin secretory response
to the intake of nutrients [101]. A precise evaluation of the
relative contribution of acidemia and uremia per se in the
insulin resistance of patients and animals with chronic renal
failure is not available. I believe, however, that acidemia plays
a significant role in insulin resistance, and that the maintenance
of a blood pH close to normal should be beneficial with respect
to the altered glucose homeostasis in end-stage renal failure.
DR. MADIAS: Regarding the pathogenesis of the hyperinsu-
linemia of uremia, what do we know about insulin release,
number of insulin receptors, insulin binding to its receptor, and
postreceptor events in this disorder? Is there resistance to
insulin's ability to suppress glucose production by the liver in
uremia?
DR. ADROGUE: The pH dependence of insulin binding to its
receptor has been well established in vitro and in vivo [102,
103]. Acidemia decreases insulin binding as well as tissue
extraction of plasma insulin [751. However, uremia without
acidosis does not impair insulin binding, insulin-receptor kinase
activity, and glycogen synthase activity. Thus uremia per se
induces insulin resistance as a result of a postreceptor defect in
the insulin-stimulated transport of glucose [104, 1051. The major
site of insulin resistance in uremia occurs in the peripheral
tissues because suppression of hepatic glucose output by insulin
is normal [101]. A substantial improvement in tissue sensitivity
to insulin is achieved with dialysis, yet full correction of the
defect is not accomplished [106—108].
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York, Stony Brook, New York): I think we
must distinguish between the diabetic patient with renal failure
and the non-diabetic with renal failure. We all have seen
diabetic patients, such as Patient I, who develop extreme
hyperglycemia consequent to the glucose load from pentoneal
dialysate. The explanation for the hyperglycemia in this circum-
stance seems reasonably straightforward. How common is such
extreme hyperglycemia in the non-diabetic patient? Although
renal failure can result in glucose intolerance, as defined by
reasonable criteria, I can't recall seeing a peritoneal dialysis
patient with truly severe hyperglycemia who wasn't diabetic.
DR. ADROGUE: I agree in general with your comment. Plasma
glucose levels higher than 180 mg/dl are uncommon in non-
diabetic patients with uremia who receive chronic peritoneal
dialysis. However, severe hyperglycemia is occasionally ob-
served in non-diabetic patients with acute or chronic renal
failure who receive multiple rapid exchanges of dialysate (that
is, hourly) containing a high glucose concentration (4.25%
dextrose) to induce a large net fluid loss. In these circum-
stances, hyperglycemic hyperosmolar encephalopathy can oc-
cur in non-diabetic uremic patients.
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DR. COHEN: Even among diabetic patients treated with
pei-itoneal dialysis, the fraction who develop extreme hypergly-
cemia is small. Do we understand why some diabetics seem to
be prone to these very severe degrees of hyperglycemia
whereas the majority are not?
DR. ADROGUE: I disagree with your comment. Severe hyper-
glycemia is a major problem commonly observed in diabetics on
peritoneal dialysis unless precautions are taken to avoid its
development. Regular insulin is usually added to the dialysis
fluid to circumvent this problem [109, 1101. Since the amount of
glucose absorbed is directly proportional to both the glucose
concentration in the dialysate instilled into the peritoneal cavity
and to the number of daily dialysate exchanges, the physician
must adjust the insulin dosage to fit the particular regimen of
peritoneal dialysis recommended for the patient [1111. Diabetics
prone to severe hyperglycemia are those involved in frequent
and/or substantial dietary indiscretions associated commonly
with a large positive fluid balance (characteristically observed
on weekends and holidays). The correction of fluid excess in
these patients is achieved by increasing the number of daily
dialysate exchanges and/or by the use of exchanges with a high
glucose concentration; both maneuvers tend to further increase
plasma glucose levels. The omission of insulin doses, poor
self-monitoring of plasma glucose, and intercurrent infections
are other important factors that can lead to uncontrolled diabe-
tes and severe hyperglycemia in uremic diabetic patients on
dialysis, especially patients receiving peritoneal dialysis.
DR. COHEN: Is mild to moderate hyperglycemia in the setting
of peritoneal dialysis problematic? Do we have any reason to
think that a high glucose level is particularly dangerous for such
patients if the levels reached do not cause symptoms?
DR. ADROGUE: Maintenance of plasma glucose at approxi-
mately normal levels is important in uremic diabetic patients in
terms of preventing the development and/or decreasing the
severity of several acute and chronic complications associated
with hyperglycemia. Acute complications of hyperglycemia
include a higher risk of severe hyperkalemia and of pulmonary
edema due to extracellular fluid volume expansion; these com-
plications result when the high extracellular glucose concentra-
tion causes rapid shifts of fluid rich in potassium out of the cells.
Chronic complications of hyperglycemia include accelerated
atherogenesis and microvascular disease (most notably in the
form of diabetic retinopathy), and increased frequency and
severity of infection. Because insulin requirements fluctuate
widely in uremic diabetic patients on dialysis, very tight glucose
control is not a reasonable goal of insulin therapy. It is prudent
and feasible to constantly maintain plasma glucose levels be-
tween 80 mg/dl and 200 mg/dl. More rigorous glucose control
substantially increases the risk of hypoglycemia, the most dread
complication in patients with altered glucose horneostasis [1101.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I have several
questions. Which specific cells within the kidney metabolize
insulin? Does the site of metabolism vary in patients with
different kinds of renal disease? Are there alterations in glucose
uptake in the insulin-insensitive tissues in uremic individuals?
Finally, is glucose uptake per se altered in uremia?
DR. ADR0GUE: Renal cells of the proximal tubule extract
insulin from the luminal fluid (filtered insulin) and peritubular
fluid, and degrade this hormone for final disposal. Although
renal ablation can lead to hyperinsulinemia, the high plasma
insulin levels observed in uremia must result from inappropri-
ately high secretory rates by the beta cells of the pancreas,
since tissue insulin extraction is not a primary modulator of
insulin levels [68]. With respect to the metabolism of insulin in
renal disease, a reduction in the renal extraction of insulin has
been found in disease states characterized by a reduced glomer-
ular filtration rate of 40 mi/mm. When the GFR is less than 20
mi/mm, a clinically significant reduction in the renal clearance
of insulin is evident [112, 113]. Hyperglycemia in uremic
patients, whether diabetic or not, increases glucose uptake in
the non-insulin-sensitive tissues. The main defect in glucose
metabolism observed in uremia, however, is in glucose disposal
by insulin-sensitive tissues, especially the skeletal muscle. A
decreased insulin-mediated glucose uptake in skeletal and adi-
pose tissues is also present in uremic non-diabetic patients, and
this defect is ameliorated by dialysis.
DR. MADIAS: In various insulin-resistant states, including
uremia, insulin-mediated extrarenal potassium uptake, both by
liver and muscle, is intact. Obviously, different transport sys-
tems mediate glucose uptake and potassium uptake, but could
you enlighten us on the current understanding of this dissocia-
tion?
DR. ADROGUE: Insulin is a major modulator of extrarenal
potassium homeostasis and promotes potassium uptake in
many cell types, including those from skeletal muscle and liver.
The hypokalemic action occurs at a very low insulin concen-
tration, and it is independent of the effect of insulin on glucose
uptake [114]. The cellular mechanisms of insulin-mediated
potassium uptake include: (I) stimulation of the Na-K-ATPase;
(2) stimulation of the sodiumlhydrogen exchanger; and (3)
depression of ionic conductance of some potassium channels.
Stimulation of the sodium-potassium pump by insulin results in
the translocation of potassium to the cell interior by the direct
action of this pump. The immediate result of insulin-mediated
stimulation of Na-K-ATPase on the electric properties of the
cell membrane is hyperpolarization of the membrane potential
(a more negative cell interior). Secondary effects promoted by
insulin-induced hyperpolarization of the cell membrane include
a new electrical gradient that favors cellular potassium entry,
and deactivation of potassium channels, thereby inhibiting the
cellular exit of potassium. Insulin promotes the cellular entry of
sodium and the cellular exit of hydrogen by stimulating the
sodium/hydrogen exchanger. The entry of sodium increases the
potassium-binding capacity of intracellular anions and stimu-
lates the sodium-potassium pump, therefore favoring cellular
potassium uptake. Insulin controls gating of the inward rectifier
potassium channel of skeletal muscle. This type of potassium
channel is relevant, as it accounts for most of the potassium
conductance of the skeletal muscle in the resting state. This
channel allows potassium to flow into cells much more easily
than to exit them. Thus, when the cell membrane is hyperpo-
larized, the high inward conductance facilitates cellular potas-
sium entry. When the cell membrane is depolarized, the low
outward conductance reduces potassium efflux. Insulin exag-
gerates the inward rectifying properties of this class of potas-
sium channel by a dual effect of stimulation of potassium entry
and depression of potassium exit.
DR. ANDREW KING (Division of Nephrology, New England
Medical Center): I was intrigued by the array of symptoms that
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you described for mild to moderate hypoglycemia; these symp-
toms are commonly observed in the dialysis unit. Have you any
idea of the frequency of this type of hypoglycemia? Has anyone
defined any long-term risks associated with chronic hypoglyce-
mia and, if so, should we be screening for this?
DR. ADROGUE: I believe that symptomatic hypoglycemia is
not uncommon in patients on chronic hemodialysis; this view is
shared by other investigators [101]. Hypoglycemia occurs in
uremic non-diabetic patients, especially in undernourished in-
dividuals and those with sepsis, which most commonly devel-
ops as a complication of an infected vascular access for chronic
dialysis. Hypoglycemia in hemodialysis patients is underdiag-
nosed because of insufficient awareness of this complication
and insufficient screening of plasma glucose levels. I recom-
mend measurement of plasma glucose with routine laboratory
evaluation and in uremic patients with evidence of failure to
thrive, acute illness, or a change in mental and/or neurologic
status. Hypoglycemia associated with renal failure has an
ominous prognosis [891. The addition of glucose to the dialysate
in hemodialysis has diminished the incidence and severity of
hypoglycemia in this patient population. We should bear in
mind that hypoglycemia has the potential for producing sudden
death and/or devastating neurologic complications, yet preven-
tion and treatment of hypoglycemia are very effective.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center): What is the cause of the kidney's inability to
mount gluconeogenesis in patients with end-stage renal dis-
ease? Does the uremic state affect the liver's capability for
gluconeogenesis?
DR. ADROGUE: Patients with end-stage renal failure who
develop spontaneous hypoglycemia have diminished gluconeo-
genesis. Because gluconeogenesis requires an adequate supply
of three-carbon precursors (lactate, alanine, glycerol), reduced
availability of these substances because of overall malnutrition,
poor caloric intake, and a decreased release of lactate by
skeletal muscle contributes to reduced glucose production. In
addition to substrate limitation, significant alterations also are
present in renal failure in the tissues responsible for gluconeo-
genesis. Renal gluconeogenesis is basically nonexistent in ure-
mic patients, yet the renal production of glucose in normal
individuals after prolonged fasting can account for almost
one-half of total endogenous glucose production. The presence
of relatively high plasma insulin levels in uremia, in spite of the
associated normo- or hypoglycemia, inhibits hepatic glucose
production. In addition, excessive alcohol intake, chronic liver
disease, and accumulation of a number of drugs that decrease
hepatic glucose production can lead to further depression of
hepatic gluconeogenesis and the development of hypoglycemia
in patients with renal failure.
DR. PEREIRA: You mentioned that patients on CAPD absorb
a large amount of glucose and consequently release a large
amount of insulin, which could have a deleterious effect. In that
case, CAPD is probably not the best mode of renal replacement
therapy. Are you making that assumption?
DR. ADROGUE: Multiple factors are responsible for the car-
bohydrate intolerance in uremia including insulin resistance,
increased levels of anti-insulin hormones (including growth
hormone, glucagon, and parathyroid hormone), acidemia, and
potassium depletion. The absorption of a large amount of
glucose consequent to CAPD using dialysate with a high
glucose concentration in patients having carbohydrate intoler-
ance of course involves potentially deleterious metabolic ef-
fects. Hyperglycemia can induce glycosylation of proteins in
various tissues and thus contribute to accelerated atherosclero-
sis. Hyperglycemia and the resulting hyperinsulinemia can lead
to hypertriglyceridemia and contribute to the abnormal profile
of plasma lipoproteins observed in uremia. Glucose absorption
in patients treated with CAPD accounts for about 20% of the
total daily energy intake and is often associated with weight
gain. In spite of the side effects resulting from the glucose
present in the dialysate, CAPD represents an excellent modality
of renal replacement therapy [115].
DR. KLEMENS MEYER (Division of Nephrology, New En-
gland Medical Center): I was unnerved by the list of drugs to
which you ascribe hypoglycemia. I must say that I was also a
little skeptical of it, particularly if the data were drawn from
patients who had other underlying reasons for hypoglycemia.
You have shown us that hemodialysis patients do have other
reasons. I would think it very hard to show that sodium
warfarin or acetaminophen was responsible for a meaningful
change in blood glucose. I wonder how many of the drugs on
your list were carefully studied. How many are on it because of
coincidence?
DR. ADR000E: More than 80% of all reported cases of severe
drug-induced hypoglycemia have occurred in undernourished
patients, most of them having significant hepatic and/or renal
disease. Renal failure is the most important predisposing factor
for hypoglycemia in patients with diabetes mellitus receiving
sulfonylureas. Insulin administration and alcohol ingestion re-
main the leading causes of disabling and lethal hypoglycemic
encephalopathy in uremic and nonuremic patients. Ingestion of
aspirin and acetaminophen have resulted in many well-docu-
mented cases of symptomatic hypoglycemia. The role of so-
dium warfarin in drug-induced hypoglycemia appears of lesser
importance. Yet all drugs listed in Table 6 are considered to be
truly responsible for the development of hypoglycemia [95].
DR. MADIA5: To what extent have researchers studied
whether dialysis improves the various abnormalities in glucose
homeostasis in uremic patients?
DR. ADROGUE: Carefully conducted studies have docu-
mented that hemodialysis significantly improves tissue sensitiv-
ity to insulin and increases insulin degradation by the liver and
skeletal muscle [101]. These effects of dialysis substantially
improve the abnormal glucose homeostasis observed in uremic
patients.
DR. RONALD PERRONE (Division of Nephrology, New En-
gland Medical Center): Can you estimate the relative propor-
tion of patients with pseudodiabetes and hypoglycemia? Could
there be one or two factors that determine whether a patient will
manifest either hypoglycemia or pseudodiabetes? Is the sole
difference caloric intake and hepatic gluconeogenesis, or are
other factors at play?
DR. ADROGUE: I stated earlier that most uremic patients have
reduced peripheral sensitivity to insulin's action and evidence
of pseudodiabetes. This process leads to either fasting or
postprandial hyperglycemia. Yet, these patients are also at risk
of hypoglycemia because of marked prolongation of the half-life
of insulin and other factors. If diabetes mellitus accompanies
uremia, these patients are at increased risk of hyperglycemia
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and hypoglycemia. The risk for the development of hypoglyce-
mia is high in uremic patients who are malnourished, have poor
caloric intake, ingest significant amounts of alcohol, have
concomitant hepatic disease, receive drugs that lead to hypo-
glycemia (including insulin therapy), receive hemodialysis with
a glucose-free dialysate, and develop generalized sepsis.
DR. COHEN: Do you recommend peritoneal dialysis for
well-nourished diabetic patients?
DR. ADROGUE: Yes, I do recommend CAPD and CCPD as
acceptable options among the multiple modalities of renal
replacement therapy. The disadvantages of the obligatory glu-
cose load associated with all peritoneal dialysis modalities, as
compared with hemodialysis, are counterbalanced by several
advantages of PD, including improved control of fluid balance,
lower incidence of hypotension and hyperkalemia, and avoid-
ance of the ocular complications (such as bleeding) associated
with the use of heparin in hemodialysis.
DR. COHEN: Would you comment on the need for insulin
treatment in patients with severe hyperglycemia? On the one
hand, as you have noted, insulin resistance is a characteristic
feature of patients with renal disease, and has a variety of
explanations. On the other hand, the first patient you discussed
is typical in that a relatively small amount of insulin was needed
to normalize an extremely high blood sugar. This observation
raises a question: did the insulin play any role in the treatment
of the hyperglycemia, or would the hyperglycemia have sub-
sided just as rapidly on its own?
DR. ADROGUE: An additional reduction in peripheral sensi-
tivity to insulin is observed in diabetics who develop renal
failure. Yet insulin requirements characteristically diminish in
patients with diabetes mellitus when they develop severe renal
insufficiency due to decreased caloric intake, prolongation of
the half-life of insulin, and other mechanisms, Since increased
hepatic glucose production is a characteristic feature of diabe-
tes, and hyperglycemia in these patients fails to fully suppress
the hepatic release of glucose, insulin administration is required
for the treatment of hyperglycemia. It is unlikely that the
hyperglycemia observed in today's first patient would have
subsided on its own in the absence of insulin administration.
DR. MADIAS: I was somewhat confused about the effect of
acidemia on insulin secretion. I believe that previous workers
have shown that ammonium-chloride-induced acidosis sup-
presses insulin secretion, but I think you mentioned that in your
studies insulin secretion was normal or high during acidemia.
Haven't you previously shown a difference between the effects
of hydrochloric acid and ketoacids on insulin secretion?
DR. ADROGUE: A dissimilar insulin secretory response oc-
curs in mineral acid acidosis as compared with organic acid
acidosis due to infusion of ketoacids [77]. Whereas metabolic
acidosis induced by hydrochloric acid administration fails to
significantly alter insulin secretion, a comparable degree of
acidemja due to ketoacid infusion increases insulin secretion.
We previously proposed that ketones, probably acting as nutri-
ents, stimulate insulin secretion; by contrast, the infusion of
hydrochloric acid, which does not have an anion for islet
oxidation, fails to stimulate insulin release [77]. The inhibition
of insulin secretion observed with ammonium chloride admin-
istration depends on the effect of ammonium on the pancreatic
islets but not of the simultaneous alteration in systemic acidity.
Acidemia of any cause, however, alters insulin binding to its
receptor and can produce postreceptor effects. A higher-than-
normal plasma insulin level can be observed in acidosis and
occurs in association with decreased tissue extraction of insulin
by hepatic and extrahepatic tissues.
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